NYU charges ResMed with patent infringement
By HME News Staff
Updated 10:19 AM CDT, Tue September 7, 2021
NEW YORK – New York University has filed a complaint for patent infringement against ResMed. The complaint, filed in Delaware, alleges that ResMed commits acts of patent infringement through the manufacture, use, offer for sale, sale and/or importation of the company’s AirSense 10 AutoSet systems that include the AutoSet algorithm and AutoRamp features. The AutoSet algorithm monitors a patient's breathing pattern to determine the ideal pressure to use for treatment; the AutoRamp feature detects when a patient is asleep, monitors their breathing pattern, and administers increasing amounts of air pressure up to a specific level. NYU argues that David Rapoport, M.D., who currently serves as the director of the Sleep Medicine Research Program at Mount Sinai in New York, and Robert Norman hold seven U.S. patents, including a “System and method for diagnosing and treatment of a breathing pattern of a patient,” that are infringed upon by ResMed’s AirSense 10. The university requests the court to enter judgment in its favor by, among other things, awarding it damages and attorney fees.
Comments